Evaluating fairness and mitigating bias in models predicting financial toxicity among patients with genitourinary cancers.
Atulya Aman Khosla(Baptist Hospital of Miami), Ishwaria M. Subbiah(The University of Texas MD Anderson Cancer Center), Anshul Saxena(Florida International University), Rohan Garje(Baptist Hospital of Miami), Ishmael Jaiyesimi(Beaumont Hospital, Royal Oak), Manas Pustake(Texas Tech University), Nitya Batra(Jacksonville College), Karan Jatwani(Roswell Park Comprehensive Cancer Center), Yagnapriya Ammakola(Beaumont Hospital, Troy), Mohammad Arfat Ganiyani(Baptist Hospital of Miami)
Cited by 0
Related Papers
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group
|Supportive Care in Cancer|2020|144
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
|Nature Reviews Clinical Oncology|2021|140
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116
Early Detection of Subclinical Visual Damage After Blast-Mediated TBI Enables Prevention of Chronic Visual Deficit by Treatment With P7C3-S243
|Investigative Ophthalmology & Visual Science|2014|91